Cessatech A/S

Equities

CESSA

DK0061411964

End-of-day quote NORDIC GROWTH MARKET Other stock markets 23:00:00 16/06/2024 BST			5-day change	1st Jan Change
6.14 ^DKK	+1.66%		+1.66%	-15.43%

06-03	Cessatech A/S Announces Superior Simulated Pain Efficacy in Children Favouring Its Lead Candidate Ct001 Relative to Its Active Comparators	CI
05-27	Cessatech A/S Reports First Patient Dosed in Final Safety Study 0202 of Lead Product Candidate CT001	CI

Cessatech A/S Reports First Patient Dosed in Final Safety Study 0202 of Lead Product Candidate CT001

May 27, 2024 at 01:53 pm

Cessatech A/S announced that the Safety Study 0202 has now been initiated with dosing of the first patient. The trial will assess safety, tolerability, analgesic effect, and feasibility of CT001 in 150 paediatric patients with moderate to severe pain, in the emergency setting. The paediatric investigation plan (PIP) for CT001 nasal spray has been approved by the European Medicines Agency, and Safety Study 0202 is part of the clinical development plan for treatment of acute pain in children.

Latest news about Cessatech A/S

Cessatech A/S Announces Superior Simulated Pain Efficacy in Children Favouring Its Lead Candidate Ct001 Relative to Its Active Comparators	06-03	CI
Cessatech A/S Reports First Patient Dosed in Final Safety Study 0202 of Lead Product Candidate CT001	05-27	CI
Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-16	CI
Cessatech A/S Announces the Paediatric Committee Agrees to Reduce the Number of Required Children in the Final Clinical Study with CT001 from 300 to 150 Children	25/10/23	CI
Cessatech Announces Last Participant Dosed in Pivotal Trial 0205 with Lead Candidate CT001	21/09/23	CI
Cessatech Wins EU Nod for Clinical Studies of Nasal Sedation Spray in Children; Shares Soar 21%	12/09/23	MT
Cessatech A/S Announces EMA's Paediatric Committee Agrees to Paediatric Investigational Plan for CT002 for Procedural Sedation	12/09/23	CI
Cessatech A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24/08/23	CI
Cessatech A/S Secures DKK 5 Million Loan Facility Agreement to Support the US Launch of its Lead Program CT001	17/08/23	CI
Cessatech A/S and Ventis Pharma Announce US Partnership for CT001	27/06/23	CI
Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	29/04/23	CI
Cessatech A/S Appoints Martin Olin as the Chairman of the Board	23/03/23	CI
Cessatech A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	01/03/23	CI
Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2022	28/02/23	CI
Cessatech A/S Auditor Raises 'Going Concern' Doubt	27/02/23	CI
Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	18/11/22	CI
Cessatech to Raise $2 Million in Rights Offer	14/11/22	MT
Cessatech Reports Successful Outcome of Pharmacokinetic Trial in Children of Lead Candidate	23/09/22	CI
Cessatech A/S Reports First Patient Dosed in Pivotal Trial of Lead Product Candidate	05/09/22	CI
Cessatech A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	19/08/22	CI
Cessatech A/S Announces Pivotal Trial 0205 Has Obtained Regulatory Approval	30/06/22	CI
Cessatech Reports Last Patient Dosed in Pharmacokinetic Trial in Children of Lead Candidate	16/05/22	CI
Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2022	19/04/22	CI

Chart Cessatech A/S

Duration

Period

More charts

Company Profile

Sector

More about the company

Income Statement Evolution

More financial data